[Urinary elimination of beta aminoisobutyric acid in malignant hemopathies].
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000621:Aminoisobutyric Acids / Q000652:urine*; D001216:Asparagine / Q000378:metabolism; D002648:Child; D005260:Female; D006689:Hodgkin Disease / Q000378:metabolism / Q000628:therapy / Q000652:urine*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy / Q000652:urine*; D007945:Leukemia, Lymphoid / Q000652:urine; D007951:Leukemia, Myeloid / Q000652:urine; D015470:Leukemia, Myeloid, Acute / Q000652:urine; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D013941:Thymine / Q000378:metabolism; D014747:Vinblastine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000621:Aminoisobutyric Acids; D014747:Vinblastine; D001216:Asparagine; D015122:Mercaptopurine; D013941:Thymine; D008727:Methotrexate
Etude de l'évolution de l'élimination urinaire de l'acide beta aminoisobutyrique au cours des hémopathies malignes.